High-throughput combinatorial screening of antiplatelet drugs for personalized medicine.

Cardiovascular disease (CVD) remains the leading cause of death worldwide. Platelet activation plays a critical role in arterial thrombotic events such as myocardial infarction. Although antiplatelet drugs are standard therapies, they are associated with risks including bleeding, gastrointestinal adverse effects, and drug resistance. Furthermore, substantial inter-individual variability in patient responses underscores the need for personalized antiplatelet regimens. These factors emphasize the importance of screening for optimal antiplatelet drugs and drug combinations tailored to individual patients. However, traditional platelet detection assays are reagent-hungry and low-throughput, making them unsuitable for high-throughput screening of antiplatelet agents. Here, we present the C-chip, a high-throughput platform for on-chip parallel screening of antiplatelet drug combinations. The C-chip miniaturizes individual screening reactions into picoliter-volume, color-coded droplets, enabling the generation of thousands of screening data points in a single experiment. We demonstrate that the C-chip can effectively identify the optimal combinations of three clinically relevant antiplatelet drugs: Aspirin, Tirofiban, and Ticagrelor. We further applied this platform to identify optimal drug combinations for five healthy volunteers, revealing marked inter-individual variability in antiplatelet drug responses.